Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines
2021
Ustun-Alkan Fulya | Bakırel Tülay | Üstüner Oya | Anlas Ceren | Cinar Suzan | Yıldırım Funda | Gürel Aydın
Masitinib mesylate, a selective tyrosine kinase inhibitor of the c-KIT receptor, is used for the treatment of mast cell tumours in dogs. Masitinib has previously been investigated in various cancers; however, its potential anticancer effect in canine mammary tumours (CMTs) is unknown. In the present paper, we investigated the antiproliferative effect of masitinib in CMT cells and its possible mechanisms of action.
显示更多 [+] 显示较少 [-]AGROVOC关键词
书目信息
出版者
Sciendo
其它主题
Vegf; Masitinib; Tyrosine kinase inhibitor; Canine mammary cancer
语言
英语
类型
Journal Article
来源
Journal of Veterinary Research, Vol 65, Iss 3, Pp 351-359 (2021)
2022-09-15
AGRIS AP
